Vicadrostat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Vicadrostat
- Molecular weight
- 317.73
- Structure (SMILES)
- C[C@]1(CO)Cc2ncn(-c3ccc(C#N)c(Cl)c3)c2C(=O)O1
- bi 690517 vicadrostat 10 mg qd empagliflozin 10 mg qd
- bi690517
- BI690517
- vicadrostat
- Vicadrostat
- vicadrostat [INN]
- VICADROSTAT [USAN]
- vicadrostat inn
- vicadrostat usan
- CAS registry numbers
- 1868065-21-7
- ChEMBL ID
- CHEMBL6068035
- InChIKey
- MCVIVPZYYMNCAW-OAHLLOKOSA-N
- PubChem compound IDs
- 118676295
- FDA ingredient codes (UNII)
- AF4VW4GA3H
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- vicadrostat
- Type
- Synthetic organic
- Drug name stem
- -stat
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP11B1
- Gene symbol
- CYP11B1
- Protein identifier
- P15538
- Median affinity
- 5.33
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP11B2
- Gene symbol
- CYP11B2
- Protein identifier
- P19099
- Median affinity
- 7.8
- Affinity units
- pIC50
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005016
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 88.14
- Calculated partition coefficient (ALogP)
- 1.86
- Calculated partition coefficient (XLogP)
- 1.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 22
- Molecular formula
- C15H12ClN3O3
- Monoisotopic mass
- 317.0567189
- Natural product
- No
Related records
Trials (8)
- A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together
- A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood
- A Study in Healthy People to Test How Vicadrostat Affects the Heart
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
- Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
- EASi-PROTKT⢠- A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease